Technology Can Help Sites and Sponsors Prepare For The Upcoming Rapid Growth Of Clinical Trials

By Taylor Davidson, Florence

The number of new clinical trials is expected to increase 5.8% each year from 2022 to 2030. But research sites already struggle to keep up with trial workloads. With 1,015 new trials starting in Q4 2021 alone, many major research sites have a backlog of anywhere from 30 to 70 studies. 

These delays have a direct impact on patient health. 22% of Phase III clinical trials fail, not because of safety or efficacy concerns, but because they last so long that they run out of funding. That means that in the U.S. alone, almost 100 life-altering therapies never make it out of Phase III because of slow trial timelines. 

What causes these slow timelines? The industry lacks standardized processes and software, which leads to inefficient document workflows and a lack of real-time visibility.